| 摘要 |
597339 Disclosed is the use of at least one specific integrin ligand, comprising cyclo-(Arg-Gly-Asp-DPhe-NMe-Val), the pharmaceutically acceptable dervatives, solvates and/or salts thereof, for the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered to a patient in a manner to achieve an about zero order kinetic over at least 24 consecutive hours, and wherein the medicament is to be used in combination with at least one further agent, selected from a) one or more alkylating chemotherapeutic agents, and b) one or more further chemotherapeutic agents other than the at least one specific integrin ligand and the one or more alkylating chemotherapeutic agents. Further disclosed is the use of at least one specific integrin ligand, comprising cyclo-(Arg-Gly-Asp-DPhe-NMe-Val), the pharmaceutically acceptable dervatives, solvates and/or salts thereof, for the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be provided to a patient by continuous administration at an about constant dosage rate for at least 24 consecutive hours, and wherein the medicament is to be used in combination with at least one further agent, selected from a) one or more alkylating chemotherapeutic agents, and b) one or more further chemotherapeutic agents other than the at least one specific integrin ligand and the one or more alkylating chemotherapeutic agents.
|
